ABBVIE (EPA:ABBV) AbbVie Files Form 8-K
Transparency directive : regulatory news
12/05/2016 22:08
Click here to download pdf version
AbbVie Files Form 8-K
NORTH CHICAGO, ILLINOIS, U.S.A., May 12, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Periodic Report on Form 8-K with the U.S. Securities and Exchange
Commission ("SEC") announcing the issuance and sale of debt securities.
AbbVie makes available free of charge on its website, its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed
pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and
amendments to those reports filed with or furnished to the SEC as soon as
reasonably practicable after AbbVie electronically files these documents with,
or furnishes them to, the SEC. These documents are posted on AbbVie's website at
www.abbvieinvestor.com.
The SEC maintains a website that contains reports, proxy statements and other
information regarding issuers that file electronically with the SEC. These
materials may be obtained electronically by accessing the SEC's home page at
http://www.sec.gov.
Copies of the above referenced information will also be made available, free of
charge, upon written request to AbbVie Inc., Investors Relations, 1 North
Waukegan Road, North Chicago, Illinois 60064, U.S.A.
CONTACT: AbbVie Inc., 1-847-938-8745